Clinical trials: Pneumococcal Infectious Disease
Pneumococcal Disease Prevention
Racial Disparities in Pneumococcal Vaccination in Managed Care
The goal of the study was to determine effectiveness of a telephone reminder to increase pneumococcal vaccination in a managed care population.
- Trial name
- NCT00229762
- Testing
- phone call from nurses - informational only
- Where
- United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Pneumococcal Infections
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed…
- Trial name
- NCT00153543
- Testing
- PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Pneumococcal Disease
A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese…
- Trial name
- NCT07019909
- Testing
- 20vPnC, 13vPnC
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Trial name
- NCT04382326
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcus; Pneumonia, Hiv
Experimental Pneumococcal Carriage in People Living With HIV
The goal of this experimental pneumococcal carriage study is to to characterise rates and determinants of experimental pneumococcal carriage in PLHIV.
- Trial name
- NCT05698225
- Testing
- Streptococcus pneumoniae serotype 6B
- Where
- Malawi
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
HIV, Pneumonia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus.
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Trial name
- NCT05794191
- Testing
- Vaccine Administration
- Where
- United States
- Volunteers
- 350,399 people
- Sponsor
- Pfizer
Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in…
- Conditions
- Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM), Invasive Pneumococcal Disease, Protection Against
- Trial name
- Nunavik2 (NCT01694329)
- Where
- Canada
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Pneumococcal Infections
Safety and Local Tolerability of Prevenar in Indian Children
This postmarketing surveillance study will evaluate the safety profile of Prevenar in Indian children. Prevenar is indicated for active immunization of infants and children from 6 weeks of age through 9 years of age against…
- Trial name
- NCT00488800
- Testing
- pneumococcal conjugate vaccine
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
This study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese subjects aged 6 to 64 years who are considered to be at increased risk of pneumococcal…
- Trial name
- NCT03571607
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 8 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) and pneumoccocal vaccine will reduce antibiotic use as compared to standard…
- Trial name
- NCT01875731
- Testing
- BPS, Guideline
- Where
- Argentina
- Volunteers
- 66 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
This study is designed to assess the effect of different dose levels of pneumococcal polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and infants.
- Trial name
- NCT02531373
- Testing
- V114 Medium Dose, V114 High Dose, V114 Medium Dose with Alternative Carrier Protein
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
The purpose of this study is to assess the indirect effects of a pneumococcal conjugate vaccine administered to infants on vaccinees' elder non-vaccinated siblings aged 3 to 7 years.
- Trial name
- FinIPcarr (NCT01311024)
- Testing
- PCV GSK1024850A, hepatitis B vaccine or hepatitis A vaccine
- Where
- Finland
- Volunteers
- 2,341 people, healthy volunteers welcome
- Sponsor
- Arto Palmu
Pneumococcal Infection, Influenza
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs), meningitis (inflammation of the brain lining)…
- Trial name
- NCT02062281
- Testing
- 23-valent pneumococcal polysaccharide vaccine, trivalent influenza vaccine, 23vPPV+TIV
- Where
- China
- Volunteers
- 2,225 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
The purpose of the study is to learn about the effects of a monovalent (single component) pneumococcal conjugate candidate (mPnC candidate) when given to toddlers between 11 and 15 months of age.
- Trial name
- NCT06116591
- Testing
- mPnC candidate, mPnC control
- Where
- 11 sites in Finland, Poland
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Pfizer
Streptococcus Pneumoniae Infections
Nasopharyngeal Streptococcus Pneumoniae Carriage
Primary Objective: Evaluation of the Carriage rate of Streptococcus pneumoniae in the nasopharynx of children Secondary Objective: Carriage rate and distribution of Streptococcus pneumoniae serotypes Estimation of prevalence rate…
- Trial name
- NCT00471822
- Where
- Taiwan
- Volunteers
- 9,707 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease, Pneumococcal Carriage
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the…
- Trial name
- RATIONALE-15 (NCT06731374)
- Testing
- PCV15, Streptococcus pneumoniae serotype 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer